Myelodysplastic syndromes: Clinical Practice Guidelines in Oncology

Peter L. Greenberg, Maria R. Baer, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, Marcel P. Devetten, Peter D. Emanuel, Harry P. Erba, Eli Estey, James Foran, Steven D. Gore, Michael Millenson, Willlis H. Navarro, Stephen D. Nimer, Margaret R. O'Donnell, Hussain I. Saba, Kathy Spiers, Richard M. Stone, Martin S. Tallman

Research output: Contribution to journalReview articlepeer-review

49 Scopus citations


These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Given the limited number of studies comparing different therapies in MDS, most of the therapeutic drugs used to treat this disease should be assessed in the context of clinical trials. Several clinical trials are ongoing to assess the efficacy of novel biospecific agents in this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important. Progress toward improving management of MDS has occurred over the past few years, and more such advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.

Original languageEnglish (US)
Pages (from-to)58-77
Number of pages20
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number1
StatePublished - Jan 2006


  • Chronic myelomonocytic leukemia
  • Cytopenias
  • Myelodysplastic syndromes
  • NCCN Clinical Practice Guidelines
  • Refractory anemia
  • Treatment

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Myelodysplastic syndromes: Clinical Practice Guidelines in Oncology'. Together they form a unique fingerprint.

Cite this